论文部分内容阅读
氯咪喹酮(Anagrelide)具有较强抗血小板聚集作用,小剂量时可致使人血小板减少。本文报道其对于治疗慢性骨髓增生性疾病伴血小板增多有较好效果。作者等初步观察了17例原发性血小板增多症(PT)、2例真性红细胞增多症(PV)伴血小板增多和例慢性粒细胞白血病(CML)伴血小板增多患者。每例病人Anagrelide初始剂量为2mg,口服q6h。密切观察血细胞计数、出血时间、部分凝血活酶生成时间、凝血酶原时间以及8例治疗前后的骨髓细胞形态学改变。对3例PT,在治疗前和治疗中还观察了Anagrelide在体外对骨髓CFU-Meg、BFU-E和CFU-GM集落生成的影响。研究发现:将Anagrelide剂量调整
Anagrelide has a strong anti-platelet aggregation effect, can cause human thrombocytopenia in small doses. This article reports its treatment of chronic myeloproliferative diseases with thrombocytosis have a good effect. The authors initially examined 17 patients with primary thrombocythemia (PT), 2 polycythemia vera (PV) with thrombocytosis and CML with thrombocytosis. Each patient Anagrelide initial dose of 2mg, oral q6h. Close observation of blood cell count, bleeding time, partial thromboplastin time, prothrombin time and 8 cases of bone marrow cells before and after treatment morphological changes. For 3 PTs, the effect of Anagrelide on CFU-Meg, BFU-E and CFU-GM colony formation in bone marrow was also observed before and during treatment. The study found that: Anagrelide dose adjustment